Vonapanitase: Ph III PATENCY-2 amended

By Julian Zhu | Mar 17, 2017 | 4:25 PM GMT

Proteon amended the double-blind, placebo-controlled, North American Phase III PATENCY-2 trial of vonapanitase given immediately after radiocephalic AVF to